The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4

Imagem de Miniatura
Arquivos
art_PINHEIRO_The_metabolic_microenvironment_of_melanomas_Prognostic_value_of_2016.PDF (1.61 MB)
Citações na Scopus
62
Tipo de produção
article
Data de publicação
2016
Editora
TAYLOR & FRANCIS INC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
PINHEIRO, Celine
MIRANDA-GONCALVES, Vera
VICENTE, Anna L. S. A.
BERARDINELLI, Gustavo N.
SCAPULATEMPO-NETO, Cristovam
COSTA, Ricardo F. A.
VIANA, Cristiano R.
REIS, Rui M.
BALTAZAR, Fatima
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CELL CYCLE, v.15, n.11, p.1462-1470, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BRAF mutations are known drivers of melanoma development and, recently, were also described as players in the Warburg effect, while this reprogramming of energy metabolism has been identified as a possible strategy for treating melanoma patients. Therefore, the aim of this work was to evaluate the expression and prognostic value of a panel of glycolytic metabolism-related proteins in a series of melanomas. The immunohistochemical expression of MCT1, MCT4, GLUT1, and CAIX was evaluated in 356 patients presenting melanoma and 20 patients presenting benign nevi. Samples included 20 benign nevi, 282 primary melanomas, 117 lymph node and 54 distant metastases samples. BRAF mutation was observed in 29/92 (31.5%) melanoma patients and 17/20 (85%) benign nevi samples. NRAS mutation was observed in 4/36 (11.1%) melanoma patients and 1/19 (5.3%) benign nevi samples. MCT4 and GLUT1 expression was significantly increased in metastatic samples, and MCT1, MCT4 and GLUT1 were significantly associated with poor prognostic variables. Importantly, MCT1 and MCT4 were associated with shorter overall survival. In conclusion, the present study brings new insights on metabolic aspects of melanoma, paving the way for the development of new-targeted therapies.
Palavras-chave
Cancer, glycolysis, melanoma, monocarboxylate transporters, Warburg effect
URI
https://observatorio.fm.usp.br/handle/OPI/16498
Referências
  1. Anderson S, 2012, ARCH PATHOL LAB MED, V136, P1385, DOI 10.5858/arpa.2011-0505-OA
  2. Ardekani GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047054
  3. Baer SC, 1997, J AM ACAD DERMATOL, V37, P575, DOI 10.1016/S0190-9622(97)70174-9
  4. Baltazar F, 2014, HISTOL HISTOPATHOL, V29, P1511
  5. Bettum IJ, 2015, CANCER LETT, V366, P71, DOI 10.1016/j.canlet.2015.06.006
  6. Carvalho KC, 2011, CLINICS, V66, P965, DOI 10.1590/S1807-59322011000600008
  7. Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
  8. Chiaradonna F, 2006, ONCOGENE, V25, P5391, DOI 10.1038/sj.onc.1209528
  9. Chiche J, 2010, J CELL MOL MED, V14, P771, DOI 10.1111/j.1582-4934.2009.00994.x
  10. Chiche J, 2010, ADV ENZYME REGUL, V50, P20, DOI 10.1016/j.advenzreg.2009.10.005
  11. Erdmann F, 2013, INT J CANCER, V132, P385, DOI 10.1002/ijc.27616
  12. Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
  13. Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56
  14. Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005
  15. Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
  16. Goydos JS, 2005, J AM COLL SURGEONS, V200, P362, DOI 10.1016/j.jamcollsurg.2004.10.032
  17. Granja S, 2015, CURR DRUG M IN PRESS
  18. Hall A, 2013, ONCOTARGET, V4, P584
  19. Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
  20. Hersey P, 2009, CLIN CANCER RES, V15, P6490, DOI 10.1158/1078-0432.CCR-09-0251
  21. Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457
  22. Ho JH, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-76
  23. Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760
  24. Koch A, 2015, ONCOTARGET, V6, P32748, DOI 10.18632/oncotarget.4977
  25. Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
  26. Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312
  27. Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
  28. Martinho O, 2009, HISTOPATHOLOGY, V55, P53, DOI 10.1111/j.1365-2559.2009.03323.x
  29. Morais-Santos F, 2015, ONCOTARGET
  30. NIEZGODA A, 2015, BIOMED RES INT, V2015, DOI [DOI 10.1155/2015/851387, 26171394]
  31. Pinheiro C, 2010, J BIOMED BIOTECHNOL, V2010, DOI 10.1155/2010/427694
  32. Pinheiro C, 2011, HISTOL HISTOPATHOL, V26, P1279
  33. Pinheiro C, 2008, VIRCHOWS ARCH, V452, P139, DOI 10.1007/s00428-007-0558-5
  34. Queiros O, 2012, J BIOENERG BIOMEMBR, V44, P141, DOI 10.1007/s10863-012-9418-3
  35. Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046
  36. Shin HJ, 2011, J CELL SCI, V124, P1077, DOI 10.1242/jcs.072207
  37. Smallbone K, 2005, J THEOR BIOL, V235, P476, DOI 10.1016/j.jtbi.2005.02.001
  38. Smith LK, 2016, PHARMACOL RES, V107, P42, DOI 10.1016/j.phrs.2016.02.009
  39. Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302
  40. Sousa B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-734
  41. Syrjanen L, 2014, APMIS, V122, P880, DOI 10.1111/apm.12251
  42. Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817
  43. Ugurel S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000236
  44. Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200
  45. vanElsas A, 1996, AM J PATHOL, V149, P883
  46. Vazquez VD, 2016, MELANOMA RES, V26, P93, DOI 10.1097/CMR.0000000000000222
  47. Wahl ML, 2002, MOL CANCER THER, V1, P617
  48. Wykoff CC, 2000, CANCER RES, V60, P7075
  49. Yamane LS, 2014, ONCOL REP, V32, P1419, DOI 10.3892/or.2014.3338
  50. Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
  51. Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
  52. Zerilli M, 2010, MODERN PATHOL, V23, P1052, DOI 10.1038/modpathol.2010.86
  53. Zhang WJ, 2015, CURR OPIN PHARMACOL, V23, P68, DOI 10.1016/j.coph.2015.05.015

Coleções
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03